SG91270A1 - Sustained release formulation - Google Patents

Sustained release formulation

Info

Publication number
SG91270A1
SG91270A1 SG200001988A SG200001988A SG91270A1 SG 91270 A1 SG91270 A1 SG 91270A1 SG 200001988 A SG200001988 A SG 200001988A SG 200001988 A SG200001988 A SG 200001988A SG 91270 A1 SG91270 A1 SG 91270A1
Authority
SG
Singapore
Prior art keywords
sustained release
release formulation
active ingredient
carbamazepine
tablet form
Prior art date
Application number
SG200001988A
Other languages
English (en)
Inventor
Daniela Licht
Marina Zholkovsky
Roman Kaplan
Michael Friedman
Abraham Yacobi
Yechiel Golander
Dan Moros
Barrie Levitt
Original Assignee
Taro Pharma Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharma Ind filed Critical Taro Pharma Ind
Publication of SG91270A1 publication Critical patent/SG91270A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG200001988A 1999-04-15 2000-04-07 Sustained release formulation SG91270A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/292,609 US6162466A (en) 1999-04-15 1999-04-15 Sustained release formulation of carbamazepine

Publications (1)

Publication Number Publication Date
SG91270A1 true SG91270A1 (en) 2002-09-17

Family

ID=23125414

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200001988A SG91270A1 (en) 1999-04-15 2000-04-07 Sustained release formulation

Country Status (10)

Country Link
US (1) US6162466A (de)
EP (1) EP1044681B1 (de)
AT (1) ATE290854T1 (de)
AU (1) AU761441B2 (de)
CA (1) CA2303973C (de)
DE (1) DE60018629T2 (de)
ES (1) ES2238982T3 (de)
NZ (1) NZ503772A (de)
SG (1) SG91270A1 (de)
ZA (1) ZA200001852B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US20070224281A1 (en) 2004-07-22 2007-09-27 Amorepacific Corporation Sustained-Release Preparations Containing Topiramate and the Producing Method Thereof
JP2008539240A (ja) * 2005-04-25 2008-11-13 テバ ファーマシュ−ティカルズ ユーエスエー， インコーポレイテッド 持続放出性処方物
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
CN101129384B (zh) * 2007-09-06 2011-07-20 河南天方药业股份有限公司 一种制备卡马西平缓释胶囊的方法
US20100285119A1 (en) * 2008-01-11 2010-11-11 Jubilant Organosys Ltd. Multiparticulate Extended Release Pharmaceutical Composition Of Carbamazepine And Process For Manufacturing The Same
CN101647784B (zh) * 2008-08-15 2012-04-11 北京科信必成医药科技发展有限公司 卡马西平缓释片及其制备方法
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08157392A (ja) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
US5888545A (en) * 1994-07-01 1999-03-30 Arzneimittelwerk Dresden Gmbh Carbamazepine medicament with retarded active substance release
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
WO2000019984A2 (de) * 1998-10-02 2000-04-13 Röhm Gmbh Überzogene arzneiformen mit kontrollierter wirkstoffabgabe

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
JP3116648B2 (ja) * 1993-04-13 2000-12-11 株式会社豊田自動織機製作所 荷役用油圧制御装置
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888545A (en) * 1994-07-01 1999-03-30 Arzneimittelwerk Dresden Gmbh Carbamazepine medicament with retarded active substance release
JPH08157392A (ja) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
WO2000019984A2 (de) * 1998-10-02 2000-04-13 Röhm Gmbh Überzogene arzneiformen mit kontrollierter wirkstoffabgabe

Also Published As

Publication number Publication date
EP1044681B1 (de) 2005-03-16
AU761441B2 (en) 2003-06-05
DE60018629T2 (de) 2006-04-13
ATE290854T1 (de) 2005-04-15
CA2303973A1 (en) 2000-10-15
EP1044681A3 (de) 2002-01-02
ZA200001852B (en) 2001-02-20
US6162466A (en) 2000-12-19
AU2641300A (en) 2000-10-19
ES2238982T3 (es) 2005-09-16
CA2303973C (en) 2009-12-22
EP1044681A2 (de) 2000-10-18
NZ503772A (en) 2001-06-29
DE60018629D1 (de) 2005-04-21

Similar Documents

Publication Publication Date Title
SG91270A1 (en) Sustained release formulation
CA2258095A1 (en) Tetrahydrolipstatin containing compositions
CA2451842A1 (en) Chewable product including active ingredient
CA2337046A1 (en) Sustained release pharmaceutical preparation
CA2119253A1 (en) Medication Vehicles Made of Solid Lipid Particles (Solid Lipid Nanospheres-SLN)
HUP9900028A3 (en) Pharmaceutically active quinazoline compounds, their production, use thereof and medicament containing them
MY125662A (en) Pharmaceutical formulations containing darifenacin
CA2307018A1 (en) Osmotic medicament releasing system
AU2002216701A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2102630A1 (en) Pharmaceutical compositions of compacted medicaments
AU6909800A (en) Metering and packaging of controlled release medication
HUP0003121A3 (en) Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance
CA2208230A1 (en) Controlled release formulation (albuterol)
CA2427815A1 (en) Controlled release hydrocodone formulations
WO2003011204A3 (en) Drug delivery systems
EP1483579A4 (de) Konjugate biologisch aktiver verbindungen, verfahren zu ihrer herstellung und verwendung, formulierung und pharmazeutische anwendungen davon
CA2311450A1 (en) Pharmaceutical aerosol compositions
FR2774288B1 (fr) Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DE69519685D1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
AU2001280764A1 (en) Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
NZ515644A (en) Oil-core compositions for the sustained release of hydrophobic drugs
AU2002214305A1 (en) Pharmaceutical preparation containing copolyvidone
UA66812C2 (uk) Препаративна форма лікарського засобу із регульованим вивільненням активної речовини
AU1671799A (en) Medicament preparation in the form of a tablet or pellet for acid-labile active substances
SE9704400D0 (sv) Porous inorganic particles as carriers for drug substances